CS MEDICA A/S: TO2 Incentive warrants issued to Diaz Capital Invest AB is exercised with 255,300 shares

Report this content

CS MEDICA’s (“CS Medica”) incentive program with Diaz Capital Invest AB is now vested with the first portion of the warrants in series TO2 being exercised with 255,300 shares at the strike price of 10.30 DKK per share. The remaing TO3 series warrants, 250,000 shares, can be exercised at a strike price of 31.50 DKK per share if they vest.

CS MEDICA currently operates with 3 series of warrants, TO1, TO2 and TO3, in addition to the incentive warrants issued to the management and employees in CS MEDICA:

  • The TO1 warrants have been submitted to all subscribers of shares in CS Medica´s IPO in September 2021. The TO1 warrants can be exercised up until 1st of September 2022. The exercise price is DKK 9,30. If all the TO1 warrants are exercised the Company will receive approx. DKK 10.8 million before deduction of transaction related costs.
  • The TO2 and the TO3 warrants have been issued to CS MEDICA´s investor relation service partner Diaz Capital Invest AB and persons/companies related to Capital Invest AB as consideration for the investor relation services performed by Diaz Capital Invest AB to CS MEDICA. The proceeds from the exercise of the warrants will be used to accelerate the growth in CS MEDICA.
  • On 16. August 2022, Diaz Capital Invest AB and persons/companies related to Capital Invest AB have exercised 255,300 out of 350,000 TO2 warrants at an exercise price of DKK 10.30 per share, which will result in DKK 2,629,590 being contributed to CS MEDICA in the near future. No additional TO2 warrants can be exercised.
  • 250,000 TO3 warrants can be exercised during the period 21 August 2023 – 4 September 2023 (both days inclusive) at an exercise price of 31.50 per share provided that certain KPI’s are met. If all the TO3 warrants are exercised an amount of DKK 7,875,000 will be contributed to CS MEDICA.

    The TO3 series warrants are the last warrants in the series approved for exercise in CS MEDICA, which is also the serie used in the valuation of CS MEDICA when seeking new capital to accelerate the growth in CS MEDICA.

The complete terms of the warrants and subscription hereof can be found in a schedule to CS MEDICA´s articles of association which are available at CS MEDICA´s homepage.  After the exercise of the TO2 series warrants, the registration of the share issue, will be performed at the Danish Companies Registration Office with the total number of shares being raised from 11.002.000 with a share capital of DKK 715.130, to 11.257.300 shares with a share capital of 731.725 DKK.
 

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags:

Subscribe

Documents & Links